Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib

BACKGROUND: Targeted therapy is an important treatment for advanced non-small cell lung cancer (NSCLC) patients with specific genetic mutations, crizotinib can prolong survival in advanced NSCLC patients with echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase (EML4-ALK) rear...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hongge, Ma, Di, Xu, Yan, Zhao, Jing, Chen, Minjiang, Liu, Xiaoyan, Zhong, Wei, Li, Junling, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733249/
https://www.ncbi.nlm.nih.gov/pubmed/31564978
http://dx.doi.org/10.2147/CMAR.S213572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733249/
https://www.ncbi.nlm.nih.gov/pubmed/31564978
http://dx.doi.org/10.2147/CMAR.S213572

Ejemplares similares